Evolving Resistance: The Interplay of p53, Chemoresistance, and Metastasis in Cancer's Journey
DOI:
https://doi.org/10.61173/fsq42722Keywords:
Cancer, Metastasis, p53, Cisplatin, DN-AktAbstract
Cancer is a growing concern around the world with more than 20 million new cases confirmed and counting. This is partly caused by the overuse of Chemotherapeutic drugs against Cancer, leading to its potency. Cancer starts with an accumulation of genetic mutations in the genome, and the ignorance to cell checks by CD8 and NK cells. The Cancer cell utilizes its hallmark capabilities and uses one of its cells to metastasizes in other areas of the body either through the perineural, circulatory, or lymphatic system. p53 is a tumor suppressor gene which repairs the mutations of the cell by conducting cell cycle arrest and inducing apoptosis. However, cancer cells can increase the expression of SB100 which can inhibit p53. One solution is to combine PRIMA-1 and CDDP which restores p53 and it’s wild type functions to induce apoptosis. This effect is increased with the use of adenoviral DN-Akt since it could increase p53 phosphorylation at Ser15.
References
[1] Han, L., Guo, X., Du, R., Guo, K., Pei, Q., & Bian, H. (2022). Identification of key genes and pathways related to cancerassociated fibroblasts in chemoresistance of ovarian cancer cells based on geo and tcga databases. Journal of Ovarian Research, 15(1). https://doi.org/10.1186/s13048-022-01003-2
[2] Malhotra, J., Malvezzi, M., Negri, E., La Vecchia, C. and Boffetta, P. (2016). Risk factors for lung cancer worldwide. European Respiratory Journal, 48(3), pp.889–902. doi: https:// doi.org/10.1183/13993003.00359-2016.
[3] Chang, P. C., Fischbein, N. J., McCalmont, T. H., Kashani- Sabet, M., Zettersten, E., Liu, A., … & Weissman, J. L.
[2004] . Perineural spread of malignant melanoma of the head and neck: clinical and imaging features. American Journal of Ophthalmology, 137(6), 1173-1174. https://doi.org/10.1016/ j.ajo.2004.04.040
[4] Kim, M. Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H., Norton, L., … & Massagué, J. (2009). Tumor selfseeding by circulating cancer cells. Cell, 139(7), 1315-1326. https://doi.org/10.1016/j.cell.2009.11.025
[5] Bi, Y., Chen, Q., Yang, M., Xing, L., & Jiang, H. (2024). Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024- 47080-3
[6] Zhou, Y., Nakajima, R., Shirasawa, M., Fikriyanti, M., Zhao, L., Iwanaga, R., … & Ohtani, K. (2023). Expanding roles of the e2f-rb-p53 pathway in tumor suppression. Biology, 12(12),
[1511] https://doi.org/10.3390/biology12121511
[7] Zhou, Y., Nakajima, R., Shirasawa, M., Fikriyanti, M., Zhao, L., Iwanaga, R., … & Ohtani, K. (2023). Expanding roles of the e2f-rb-p53 pathway in tumor suppression. Biology, 12(12),
[1511] https://doi.org/10.3390/biology12121511
[8] Schmitt, C. A., Fridman, J. S., Yang, M., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002). Dissecting p53 tumor suppressor functions in vivo. Cancer Cell, 1(3), 289-298. https:// doi.org/10.1016/s1535-6108(02)00047-8
[9] Pang, M., Georgoudaki, A., Lambut, L., Johansson, J., Tabor, V., Hagikura, K., … & Fuxe, J. (2015). Tgf-β1-induced emt promotes targeted migration of breast cancer cells through the lymphatic system by the activation of ccr7/ccl21-mediated chemotaxis. Oncogene, 35(6), 748-760. https://doi.org/10.1038/ onc.2015.133
[10] Kim, M. Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H., Norton, L., … & Massagué, J. (2009). Tumor selfseeding by circulating cancer cells. Cell, 139(7), 1315-1326. https://doi.org/10.1016/j.cell.2009.11.025
[11] Wyk, H. C. v., Going, J. J., Horgan, P. G., & McMillan, D. C. (2017). The role of perineural invasion in predicting survival in patients with primary operable colorectal cancer: a systematic review. Critical Reviews in Oncology/Hematology, 112, 11-20.
[12] De Pergola, G. and Silvestris, F. (2013). Obesity as a Major Risk Factor for Cancer. Journal of Obesity, 2013, pp.1–11. doi: https://doi.org/10.1155/2013/291546.
[13] Unger, T., Sionov, R., Moallem, E. et al. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene 18, 3205–3212 (1999). https://doi.org/10.1038/sj.onc.1202656
[14] Souza, L. C. d. M. e., Faletti, A., Veríssimo, C. P., Stelling, M. P., & Borges, H. L. (2022). P53 signaling on microenvironment and its contribution to tissue chemoresistance. Membranes, 12(2), 202. https://doi.org/10.3390/membranes12020202
[15] Malhotra, J., Malvezzi, M., Negri, E., La Vecchia, C. and Boffetta, P. (2016). Risk factors for lung cancer worldwide. European Respiratory Journal, 48(3), pp.889–902. doi: https:// doi.org/10.1183/13993003.00359-2016.
[16] Fang, D., Hu, H., Zhao, K., Xu, A., Yu, C., Zhu, Y., … & Wu, X. (2023). Mlf2 negatively regulates p53 and promotes colorectal carcinogenesis. Advanced Science, 10(26). https://doi. org/10.1002/advs.202303336
[17] Gao, X., Zheng, X., Zhang, Y., Dong, L., Sun, L., Zhao, N., … & Wang, Y. (2022). Deficient or r273h and r248w mutations of p53 promote chemoresistance to 5-fu via tcf21/cd44 axismediated enhanced stemness in colorectal carcinoma. Frontiers in Cell and Developmental Biology, 9. https://doi.org/10.3389/ fcell.2021.788331
[18] Yang, T., Cheng, J., You, J., Yan, B., Liu, H., & Li, F. (2018). S100b promotes chemoresistance in ovarian cancer stem cells by regulating p53. Oncology Reports. https://doi.org/10.3892/ or.2018.6527
[19] He, Y., Rajantie, I., Pajusola, K., Jeltsch, M., Holopainen, T., Ylä‐Herttuala, S., … & Alitalo, K. (2005). Vascular endothelial cell growth factor receptor 3–mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Research, 65(11), 4739-4746. https:// doi.org/10.1158/0008-5472.can-04-4576
[20] Unger, T., Sionov, R., Moallem, E. et al. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene 18, 3205–3212 (1999). https://doi.org/10.1038/sj.onc.1202656
[21] Kobayashi, N., Abedini, M. R., Sakuragi, N., & Tsang, B. K.
[2013] . Prima-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for akt down-regulation. Journal of Ovarian Research, 6(1). https://doi. org/10.1186/1757-2215-6-7
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
